Skip to content
value.today

Provectus Pharmaceuticals Inc.

Formerly ZAMAGE DIGITAL IMAGING INC., SPM GROUP INC.

Total raised
$24 M
5 rounds on record
Latest round
$5 M
Apr 2011
First round on record
Apr 2009
Today
Went public
See the company page

Provectus Pharmaceuticals Inc. is listed today as Provectus Biopharmaceuticals Inc.: market value, financials and filings are on its company page.

Funding rounds

5 counted as startup funding, 5 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Provectus Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2014$3 MPrivate placement after listing$2 to $10 million

Provectus Pharmaceuticals Inc.: Private sale, Apr 2014

Investors in this round

17 investors had bought by the notice of Apr 17, 2014: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Provectus Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $5 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$334,587
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eric A. Wachter · Executive Officer · Chief Technology Officer
  • H. Craig Dees · Executive Officer, Director · CEO
  • Peter R. Culpepper · Executive Officer · CFO, COO, CAO
  • Timothy C. Scott · Executive Officer, Director · President
  • Alfred E. Smith IV · Director
  • Jan C. Koe · Director
  • Kelly M. McMasters · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Network 1 Financial Securities, Inc. (CRD 13577) · Red Bank, New JerseySold in CT, FL, IL, NY, OH, TX, VA, and outside the US

Remarks in the notice

  • On fees: “Placement agent will receive: (i) 10% commission of the aggregate purchase price of the securities sold; (ii) 3% of the offering proceeds as non-accountable expenses; and (iii) cashless warrants equal to 15% of total units sold with $2.50 exercise price.”

Signed by Peter R. Culpepper, Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 17, 2014. Read the notice at the SEC.

equity, optionsSEC
Mar 2013$8 MPrivate placement after listing$2 to $10 million

Provectus Pharmaceuticals Inc.: Private sale, Mar 2013

Investors in this round

67 investors had bought by the notice of Sep 26, 2013: 67 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Provectus Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $16 M offered; $8 M still to sell
Smallest investment taken
$25,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$1,600,000
Finders' fees
none
Paid to its own people
$1,000,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Nevada

People named in the notice

  • Eric A. Wachter · Executive Officer · Chief Technology Officer
  • H. Craig Dees · Executive Officer, Director · CEO
  • Peter R. Culpepper · Executive Officer · CFO, COO, CAO
  • Timothy C. Scott · Executive Officer, Director · President
  • Alfred E. Smith IV · Director
  • Jan C. Koe · Director
  • Kelly M. McMasters · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Network 1 Financial Securities, Inc. (CRD 13577) · Red Bank, New JerseySold in CT, FL, IL, KY, MN, NC, NJ, NY, OH, PA, TN, TX, VA, WI, and outside the US
  • Maxim Group LLC (CRD 1207087) · New York, New YorkSold in AK, AZ, CA, CO, CT, FL, GA, HI, IL, IN, LA, MA, MD, MI, MO, NC, NJ, NY, OH, OK, PA, PR, SC, TN, TX, VA, VT, WA, WI

Remarks in the notice

  • On fees: “Placement agent will receive a 10% commission plus warrants to purchase 10% of the aggregate number of shares of common stock issued in the offering, with an exercise price of $1.00 per share.”

Signed by Peter R. Culpepper, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 26, 2013. Read the notice at the SEC.

equity, optionsSEC
Feb 2013$3 MPrivate placement after listing$2 to $10 million

Provectus Pharmaceuticals Inc.: Private sale, Feb 2013

Investors in this round

3 investors had bought by the notice of Mar 8, 2013: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Provectus Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Eris A. Wachter · Executive Officer · Chief Technology Officer
  • H. Craig Dees · Executive Officer · CEO
  • Peter R. Culpepper · Promoter, Executive Officer · CFO, COO, CAO
  • Timothy C. Scott · Executive Officer, Director · President
  • Alfred E. Smith IV · Director
  • Jan C. Koe · Director
  • Kelly M. McMasters · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Peter R. Culpepper, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 8, 2013. Read the notice at the SEC.

equity, optionsSEC
Nov 2012$2 MPrivate placement after listing$2 to $10 million

Provectus Pharmaceuticals Inc.: Private sale, Nov 2012

Investors in this round

5 investors had bought by the notice of Nov 19, 2012: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Provectus Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $5 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$500,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Nevada

People named in the notice

  • Eric A. Wachter · Executive Officer · Chief Technology Officer
  • H. Craig Dees · Executive Officer, Director · CEO
  • Peter R. Culpepper · Executive Officer · CFO, COO, CAO
  • Timothy C. Scott · Executive Officer, Director · President
  • Alfred E. Smith IV · Director
  • Jan C. Koe · Director
  • Kelly M. McMasters · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Network 1 Financial Securities, Inc. (CRD 13577) · Red Bank, New JerseySold in FL, TN, TX

Remarks in the notice

  • On fees: “Placement agent will receive warrants to purchase up to 10% of the aggregate number of shares of common stock issued in the Offering, with an exercise price of $1.00 per share, plus a 10% commission (5% commission for sales to the issuer's affiliates).”

Signed by Peter R. Culpepper, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 19, 2012. Read the notice at the SEC.

equity, optionsSEC
Mar 2012$2 MPrivate placement after listing$2 to $10 million

Provectus Pharmaceuticals Inc.: Private sale, Mar 2012

Investors in this round

16 investors had bought by the notice of Aug 3, 2012: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Provectus Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $5 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Alfred E. Smith IV · Director, Executive Officer · Vice President
  • Eric A. Wachter · Executive Officer · Chief Technology Officer
  • H. Craig Dees · Executive Officer, Director · CEO
  • Peter R. Culpepper · Executive Officer · CFO, COO, CAO
  • Timothy C. Scott · Executive Officer, Director · President
  • Jan C. Koe · Director
  • Kelly M. McMasters · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Network 1 Financial Securities, Inc. (CRD 13577) · Red Bank, New JerseySold in FL, KY, NJ, NY, OH, TX, WI, and outside the US

Remarks in the notice

  • On fees: “Company will the issue placement agent warrants to purchase up to 20% of aggregate amount of shares issued at exercise price of $1.12 per share for five years”

Signed by Peter R. Culpepper, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 3, 2012. Read the notice at the SEC.

equity, optionsSEC
Apr 2011$5 MNo. 5$2 to $10 million

Provectus Pharmaceuticals Inc.: Raise no. 5, Apr 2011

Investors in this round

26 investors had bought by the notice of May 5, 2011: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Provectus Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Craig H. Dees · Executive Officer, Director
  • Peter R. Culpepper · Executive Officer
  • Timothy C. Scott · Executive Officer, Director
  • Eric A. Wachter · Director
  • Kelly M. McMasters · Director
  • Stuart R. Fuchs · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Network 1 Financial Securities, Inc. (CRD 13577) · Red Bank, New JerseySold in CT, DC, FL, IL, MI, MN, NJ, NY, OH, OR, PA, TX, VA

Remarks in the notice

  • On fees: “Network 1 Financial Securities, Inc. will receive, as a sales commission, warrants to purchase up to 20% of the common stock issued at closing to investors solicited by such placement agent.”

Signed by Peter R. Culpepper, Chief Financial Officer. Source: SEC Form D, newest notice filed May 5, 2011. Read the notice at the SEC.

equity, optionsSEC
Mar 2010$1 MNo. 4Under $2 million

Provectus Pharmaceuticals Inc.: Raise no. 4, Mar 2010

Investors in this round

14 investors had bought by the notice of Apr 6, 2010: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Provectus Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$127,190
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Nevada

People named in the notice

  • Craig H. Dees · Executive Officer, Director
  • Peter R. Culpepper · Executive Officer
  • Timothy C. Scott · Executive Officer, Director
  • Eric A. Wachter · Director
  • Kelly M. McMasters · Director
  • Stuart R. Fuchs · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • William David Vellon (CRD 1954258) · broker-dealer Brewer Financial Services, LLC (CRD 132558) · Chicago, IlSold in no state named
  • Asher Wolmark (CRD 2064857) · broker-dealer Brewer Financial Services, LLC (CRD 132558) · Chicago, IlSold in no state named

Signed by Peter R. Culpepper, Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 6, 2010. Read the notice at the SEC.

equity, optionsSEC
Mar 2010$8 MNo. 3$2 to $10 million

Provectus Pharmaceuticals Inc.: Raise no. 3, Mar 2010

Investors in this round

36 investors had bought by the notice of Mar 24, 2010: 36 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Provectus Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $10 M offered; $2 M still to sell
Smallest investment taken
$25,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$793,750
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Nevada

People named in the notice

  • Craig H. Dees · Executive Officer, Director
  • Peter R. Culpepper · Executive Officer
  • Timothy C. Scott · Executive Officer, Director
  • Eric A. Wachter · Director
  • Kelly M. McMasters · Director
  • Stuart R. Fuchs · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · broker-dealer 0 (CRD 0) · New York, NySold in no state named

Signed by Peter R. Culpepper, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 24, 2010. Read the notice at the SEC.

equity, optionsSEC
May 2009$3 MNo. 2$2 to $10 million

Provectus Pharmaceuticals Inc.: Raise no. 2, May 2009

Investors in this round

47 investors had bought by the notice of Jun 30, 2009: 47 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Provectus Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $4 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$271,200
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Nevada

People named in the notice

  • Eric A. Wachter · Executive Officer, Director
  • H. Craig Dees · Executive Officer, Director
  • Peter R. Culpepper · Executive Officer
  • Timothy C. Scott · Executive Officer, Director
  • Kelly M. McMasters · Director
  • Stuart Fuchs · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Network 1 Financial Securities Inc. (CRD 13577) · Red Bank, NjSold in no state named
  • Maxim Group LLC (CRD 120708) · New York, NySold in no state named

Signed by Peter R. Culpepper, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 30, 2009. Read the notice at the SEC.

equity, optionsSEC
Apr 2009$8 MNo. 1$2 to $10 million

Provectus Pharmaceuticals Inc.: Raise no. 1, Apr 2009

Investors in this round

90 investors had bought by the notice of Mar 26, 2010: 90 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Provectus Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $10 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$761,333
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Nevada

People named in the notice

  • Craig H. Dees · Executive Officer, Director
  • Eric A. Wachter · Executive Officer, Director
  • Peter R. Culpepper · Executive Officer
  • Timothy C. Scott · Executive Officer, Director
  • Kelly M. McMasters · Director
  • Stuart R. Fuchs · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Network 1 Financial Securities, Inc. (CRD 13577) · Red Bank, NjSold in no state named
  • Maxim Group LLC (CRD 120708) · New York, NySold in no state named

Remarks in the notice

  • On fees: “Commission as shown does not include a non-accountable expense allowance of 3% of gross proceeds and common stock equal to 10% of the total number of shares of common stock issued at closing.”

Signed by Peter R. Culpepper, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Mar 26, 2010. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Provectus Biopharmaceuticals Inc., its revenue in fiscal 2025 came from these business segments: Clinical Stage Biotechnology $340,000 (100%).

    Annual report (SEC XBRL) · Dec 2025

  • Provectus Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2014).

    SEC Form D · Apr 2014

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Apr 2014

Products and services#

No products or services of Provectus Pharmaceuticals Inc. are on record.

Investors#

1 named in official filings. Open an investor to see everything it has backed.

Investors in Provectus Pharmaceuticals Inc.
InvestorKindAmountRoundRoleSource
Jeffrey Allen MorrisPersonnot statednot statedHeld Series D-1 preferred stock, 10% owner (Form 3, 2023)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 90 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Provectus Pharmaceuticals Inc.
NameRoleNamed in
Eric A. WachterChief Technology OfficerApr 2014
H. Craig DeesCEOApr 2014
Peter R. CulpepperCFO, COO, CAOApr 2014
Timothy C. ScottPresidentApr 2014
Eris A. WachterChief Technology OfficerMar 2013
Alfred E. Smith IVVice PresidentAug 2012
Craig H. DeesExecutive officerMay 2011
Eric A WachterExecutive officerAug 2009
Alfred E. Smith IVDirectorApr 2014
H. Craig DeesCEOApr 2014
Jan C. KoeDirectorApr 2014
Kelly M. McMastersDirectorApr 2014
Timothy C. ScottPresidentApr 2014
Craig H. DeesDirectorMay 2011
Eric A. WachterDirectorMay 2011
Stuart R. FuchsDirectorMay 2011
Eric A WachterDirectorAug 2009
Stuart FuchsDirectorAug 2009
Peter R. CulpepperCFO, COO, CAOMar 2013

Went public since 2011. Its SEC number is that of a company listed on a stock exchange.